L

Lycia Therapeutics, Inc.

LYCAFiled

Lycia Therapeutics, Inc. · Nasdaq Global Market · latest filing 2026-10-05

Report source
One-minute decisionBASIC RESEARCHSource completeness · 48%

Lycia’s preliminary IPO remains incomplete, with blank pricing, share counts, proceeds and listing approval pending.

As of the October 5, 2026 preliminary prospectus, Lycia had not disclosed IPO pricing or share counts and had no public market.

Where does the money go?Awaiting verificationS-1 · 2026-10-05
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointEffectiveness of the registration statement, pricing and any confirmed listing or trading commencement are not disclosed.S-1 · 2026-10-05

Capital destination

Awaiting verification

S-1 · 2026-10-05

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
Next checkEffectiveness of the registration statement, pricing and any confirmed listing or trading commencement are not disclosed.
Latest filing2026-10-05

Capital destination

Awaiting verification

S-1 · 2026-10-05

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1 ↗

Holder data awaits verification

The supplied evidence states that existing insiders and 5% holders will retain significant voting influence, but percentages and holder-level amounts are blank or incomplete. · 2026-10-05

The supplied evidence states that existing insiders and 5% holders will retain significant voting influence, but percentages and holder-level amounts are blank or incomplete.

One disclosed holder; not a complete ownership distribution.Check the source · S-1 ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

Lycia has limited operating history, no approved products and has not completed any clinical trials, making success difficult to evaluate.

Potential impact
Awaiting verification
Monitor
Effectiveness of the registration statement, pricing and any confirmed listing or trading commencement are not disclosed.
SEC EDGAR

S-1

2026-10-05

Open SEC filing ↗